AbbVie Acquires Novel Psychedelic Bretisilocin for MDD Treatment
AbbVie has acquired bretisilocin, a novel psychedelic compound, from Gilgamesh Pharmaceuticals. This move aims to expedite its development for treating moderate-to-severe major depressive disorder (MDD).
Bretisilocin, a short-acting serotonin 5-HT receptor agonist and 5-HT releaser, is designed to address challenges faced by classic psychedelic compounds. It is currently in Phase 2 clinical trials for MDD.
Daniel Mikol, AbbVie's Vice President of Neuroscience Development, is overseeing the drug's development. He emphasizes accelerating its progress following AbbVie's acquisition. The company's mission includes discovering and delivering innovative medicines across key therapeutic areas, including neuroscience.
AbbVie's acquisition of bretisilocin signals its commitment to delivering innovative mental health treatment options. The company will accelerate the drug's development, aiming to provide a new solution for patients with moderate-to-severe depression.
Read also:
- Actively Black's Lanny Smith Declares NYFW Show 'Not a Fashion Show', but a Civil Rights Tribute
- Upper Dublin Launches Tech Trek: A Digital Well-being Resource for Families
- Tom Holland: Christianity's Role in Shaping Western Thought
- Historian Ute Frevert Explores 'Constitutional Feelings' Among Far-Right AfD Voters
